Cargando…
Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL
BACKGROUND: Neuroblastoma (NB) is a common solid malignancy in children that is associated with a poor prognosis. Although the novel small molecular compound Dimethylaminomicheliolide (DMAMCL) has been shown to induce cell death in some tumors, little is known about its role in NB. METHODS: We exami...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613996/ https://www.ncbi.nlm.nih.gov/pubmed/34819091 http://dx.doi.org/10.1186/s12935-021-02330-y |
_version_ | 1784603762953814016 |
---|---|
author | Zhang, Simeng Hua, Zhongyan Ba, Gen Xu, Ning Miao, Jianing Zhao, Guifeng Gong, Wei Liu, Zhihui Thiele, Carol J. Li, Zhijie |
author_facet | Zhang, Simeng Hua, Zhongyan Ba, Gen Xu, Ning Miao, Jianing Zhao, Guifeng Gong, Wei Liu, Zhihui Thiele, Carol J. Li, Zhijie |
author_sort | Zhang, Simeng |
collection | PubMed |
description | BACKGROUND: Neuroblastoma (NB) is a common solid malignancy in children that is associated with a poor prognosis. Although the novel small molecular compound Dimethylaminomicheliolide (DMAMCL) has been shown to induce cell death in some tumors, little is known about its role in NB. METHODS: We examined the effect of DMAMCL on four NB cell lines (NPG, AS, KCNR, BE2). Cellular confluence, survival, apoptosis, and glycolysis were detected using Incucyte ZOOM, CCK-8 assays, Annexin V-PE/7-AAD flow cytometry, and Seahorse XFe96, respectively. Synergistic effects between agents were evaluated using CompuSyn and the effect of DMAMCL in vivo was evaluated using a xenograft mouse model. Phosphofructokinase-1, liver type (PFKL) expression was up- and down-regulated using overexpression plasmids or siRNA. RESULTS: When administered as a single agent, DMAMCL decreased cell proliferation in a time- and dose-dependent manner, increased the percentage of cells in SubG1 phase, and induced apoptosis in vitro, as well as inhibiting tumor growth and prolonging survival in tumor-bearing mice (NGP, BE2) in vivo. In addition, DMAMCL exerted synergistic effects when combined with etoposide or cisplatin in vitro and displayed increased antitumor effects when combined with etoposide in vivo compared to either agent alone. Mechanistically, DMAMCL suppressed aerobic glycolysis by decreasing glucose consumption, lactate excretion, and ATP production, as well as reducing the expression of PFKL, a key glycolysis enzyme, in vitro and in vivo. Furthermore, PFKL overexpression attenuated DMAMCL-induced cell death, whereas PFKL silencing promoted NB cell death. CONCLUSIONS: The results of this study suggest that DMAMCL exerts antitumor effects on NB both in vitro and in vivo by suppressing aerobic glycolysis and that PFKL could be a potential target of DMAMCL in NB. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02330-y. |
format | Online Article Text |
id | pubmed-8613996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86139962021-11-29 Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL Zhang, Simeng Hua, Zhongyan Ba, Gen Xu, Ning Miao, Jianing Zhao, Guifeng Gong, Wei Liu, Zhihui Thiele, Carol J. Li, Zhijie Cancer Cell Int Primary Research BACKGROUND: Neuroblastoma (NB) is a common solid malignancy in children that is associated with a poor prognosis. Although the novel small molecular compound Dimethylaminomicheliolide (DMAMCL) has been shown to induce cell death in some tumors, little is known about its role in NB. METHODS: We examined the effect of DMAMCL on four NB cell lines (NPG, AS, KCNR, BE2). Cellular confluence, survival, apoptosis, and glycolysis were detected using Incucyte ZOOM, CCK-8 assays, Annexin V-PE/7-AAD flow cytometry, and Seahorse XFe96, respectively. Synergistic effects between agents were evaluated using CompuSyn and the effect of DMAMCL in vivo was evaluated using a xenograft mouse model. Phosphofructokinase-1, liver type (PFKL) expression was up- and down-regulated using overexpression plasmids or siRNA. RESULTS: When administered as a single agent, DMAMCL decreased cell proliferation in a time- and dose-dependent manner, increased the percentage of cells in SubG1 phase, and induced apoptosis in vitro, as well as inhibiting tumor growth and prolonging survival in tumor-bearing mice (NGP, BE2) in vivo. In addition, DMAMCL exerted synergistic effects when combined with etoposide or cisplatin in vitro and displayed increased antitumor effects when combined with etoposide in vivo compared to either agent alone. Mechanistically, DMAMCL suppressed aerobic glycolysis by decreasing glucose consumption, lactate excretion, and ATP production, as well as reducing the expression of PFKL, a key glycolysis enzyme, in vitro and in vivo. Furthermore, PFKL overexpression attenuated DMAMCL-induced cell death, whereas PFKL silencing promoted NB cell death. CONCLUSIONS: The results of this study suggest that DMAMCL exerts antitumor effects on NB both in vitro and in vivo by suppressing aerobic glycolysis and that PFKL could be a potential target of DMAMCL in NB. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02330-y. BioMed Central 2021-11-24 /pmc/articles/PMC8613996/ /pubmed/34819091 http://dx.doi.org/10.1186/s12935-021-02330-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Primary Research Zhang, Simeng Hua, Zhongyan Ba, Gen Xu, Ning Miao, Jianing Zhao, Guifeng Gong, Wei Liu, Zhihui Thiele, Carol J. Li, Zhijie Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL |
title | Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL |
title_full | Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL |
title_fullStr | Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL |
title_full_unstemmed | Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL |
title_short | Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL |
title_sort | antitumor effects of the small molecule dmamcl in neuroblastoma via suppressing aerobic glycolysis and targeting pfkl |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613996/ https://www.ncbi.nlm.nih.gov/pubmed/34819091 http://dx.doi.org/10.1186/s12935-021-02330-y |
work_keys_str_mv | AT zhangsimeng antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT huazhongyan antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT bagen antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT xuning antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT miaojianing antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT zhaoguifeng antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT gongwei antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT liuzhihui antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT thielecarolj antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl AT lizhijie antitumoreffectsofthesmallmoleculedmamclinneuroblastomaviasuppressingaerobicglycolysisandtargetingpfkl |